Study to Evaluating PRO-240 Ophthalmic Solution Compared to Optive®
Status:
NOT_YET_RECRUITING
Trial end date:
2027-01-30
Target enrollment:
Participant gender:
Summary
This is a phase I clinical study to evaluating safety and tolerability of PRO-240 ophthalmic solution through the incidence of unexpected adverse events, as well as through changes in Best Corrected Visual Acuity (BCVA), and the incidence of stinging after its administration, compared to Optive®.